Recent Updates — MOLN

Molecular Partners AG announced it intends to reduce its current workforce by no more than 55 positions, representing approximately 44% of all roles, as part of a strategic streamlining and deepened focus on radiopharmaceuticals. The company reported CHF 57.5 million in cash and cash equivalents as of September 30, 2026, which is expected to fund operations into late 2027. For the nine months ended September 30, 2026, the company recorded a net loss attributable to shareholders of CHF 38.4 million, compared to CHF 49.0 million in the prior year period. The restructuring consultation process has been initiated under Swiss employment law, with full implementation expected by Q2 2027 and cost reductions becoming effective early in H2 2027. Molecular Partners AG is a clinical-stage biopharmaceutical company pioneering designed ankyrin repeat proteins (DARPins) to treat serious diseases, with a current focus on oncology and virology.

Molecular Partners AG announced the dosing of first patients in the TACTIC Phase 2 proof-of-concept study of MP0317 in combination with chemoimmunotherapy for advanced biliary tract carcinoma. The randomized, multicenter study aims to recruit 75 patients with a 2-to-1 design and expects a data update in 2027 with trial completion in 2026. Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics for cancer patients.